Helicobacter pylori eradication in West Asia: A review

World Journal of Gastroenterology

Volumn 20, Issue 30, 2014, Pages 10355-10367

  Fakheri, Hafez ^a   Bari, Zohreh ^b   Aarabi, Mohsen ^c   Malekzadeh, Reza ^d  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Eradication; Helicobacter pylori; Recurrence; Resistance; West Asia

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BISMUTH; BISMUTH CITRATE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ESOMEPRAZOLE; FURAZOLIDONE; GATIFLOXACIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; RIFAMPICIN; TETRACYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASIA; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; DRUG TREATMENT FAILURE; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; WEST ASIAN; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG COST; DRUG EFFECTS; ECONOMICS; HELICOBACTER INFECTIONS; MICROBIOLOGY; PATHOGENICITY; RECURRENT DISEASE; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; ASIA, WESTERN; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; RECURRENCE; TREATMENT FAILURE;

EID: 84920622634     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i30.10355     Document Type: Article

References (114)

1. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16 Suppl 1: 3-15 [PMID: 11849122 DOI: 10.1046/j.1365-2036.2002.0160s1003.x]
2. Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, Yoonessi A, Tavangar M, Abedi BA, Sotoudehmanesh R, Pourshams A, Asgari AA, Doulatshahi S, Alizadeh BZ, Arshi S, Madjidpoor A, Mir Moomen S, Fleischer DE. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol 2004; 57: 37-42 [PMID: 14693833 DOI: 10.1136/jcp.57.1.37]
3. Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol 1995; 7: 427-433 [PMID: 7614105]
4. Bani-Hani KE, Hammouri SM. Prevalence of Helicobacter pylori in Northern Jordan. Endoscopy based study. Saudi Med J 2001; 22: 843-847 [PMID: 11744938]
5. Bener A, Uduman SA, Ameen A, Alwash R, Pasha MA, Usmani MA, AI-Naili SR, Amiri KM. Prevalence of Helicobacter pylori infection among low socio-economic workers. J Commun Dis 2002; 34: 179-184 [PMID: 14703052]
6. Us D, Hasçelik G. Seroprevalence of Helicobacter pylori infection in an Asymptomatic Turkish population. J Infect 1998; 37: 148-150 [PMID: 9821089 DOI: 10.1016/S0163-4453(98)80169-2]
7. Al-Moagel MA, Evans DG, Abdulghani ME, Adam E, Evans DJ, Malaty HM, Graham DY. Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia, and comparison of those with and without upper gastrointestinal symptoms. Am J Gastroenterol 1990; 85: 944-948 [PMID: 2375321]
8. Al-Shamahy HA. Seroprevalence of Helicobacter pylori among children in Sana'a, Yemen. Ann Saudi Med 2005; 25: 299-303 [PMID: 16212122]
9. Radhakrishnan S, al Nakib B, Kalaoui M, Patric J. Helicobacter pylori-associated gastritis in Kuwait: endoscopybased study in symptomatic and asymptomatic children. J Pediatr Gastroenterol Nutr 1993; 16: 126-129 [PMID: 8450377 DOI: 10.1097/00005176-199302000-00005]
10. Lee SY. Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised? J Gastroenterol Hepatol 2012; 27: 200-211 [PMID: 22098099 DOI: 10.1111/j.1440-1746.2011.06961.x]
11. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection - The Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
12. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]
13. Safaralizadeh R, Siavoshi F, Malekzadeh R, Akbari MR, Derakhshan MH, Sohrabi MR, Massarrat S. Antimicrobial effectiveness of furazolidone against metronidazole-resistant strains of Helicobacter pylori. East Mediterr Health J 2006; 12: 286-293 [PMID: 17037696]
14. Majlesi A, Sayedin Khorasani M, Khalilian AR, Aslani MM, Jaefari M, Alikhani MY. Antibiotic Susceptibility of Helicobacter pylori Clinical Isolates in Hamadan, West of Iran. Int J Entric Pathog 2013; 1: 9-11 [DOI: 10.5812/ijep.12985]
15. Bindayna KM. Antibiotic susceptibilities of Helicobacter pylori. Saudi Med J 2001; 22: 53-57 [PMID: 11255612]
16. Onder G, Aydin A, Akarca U, Tekin F, Ozutemiz O, Ilter T. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007; 41: 747-750 [PMID: 17700422 DOI: 10.1097/MCG.0b013e31802e7ee7]
17. Sezgin O, Aslan G, Altintaş E, Tezcan S, Serin MS, Emekdaş G. Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey. Turk J Gastroenterol 2008; 19: 163-167 [PMID: 19115151]
18. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 2010; 8: 59-70 [PMID: 20014902 DOI: 10.1586/eri.09.113]
19. Malekzadeh R, Merat S, Derakhshan MH, Siavoshi F, Yazdanbod A, Mikaeli J, Sotoudemanesh R, Sotoudeh M, Farahvash MJ, Nasseri-Moghaddam S, Pourshams A, Dolatshahi S, Abedi B, Babaei M, Arshi S, Majidpour A. Low Helicobacter pylori eradication rates with 4-and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003; 18: 13-17 [PMID: 12519218 DOI: 10.1046/j.1440-1746.2003.02897.x]
20. Mirbagheri SA, Hasibi M, Abouzari M, Rashidi A. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. Pylori eradication: a comparative three-armed randomized clinical trial. World J Gastroenterol 2006; 12: 4888-4891 [PMID: 16937475]
21. Mirzaee V, Rezahosseini O. Randomized control trial: Comparison of Triple Therapy plus Probiotic Yogurt vs. Standard Triple Therapy on Helicobacter Pylori Eradication. Iran Red Crescent Med J 2012; 14: 657-666 [PMID: 23285418]
22. Aminian K, Farsad F, Ghanbari A, Fakhreih S, Hasheminasab SM. A randomized trial comparing four Helicobacter pylori eradication regimens: standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy. Trop Gastroenterol 2010; 31: 303-307 [PMID: 21568147]
23. Riahizadeh S, Malekzadeh R, Agah S, Zendehdel N, So-toudehmanesh R, Ebrahimi-Dariani N, Pourshams A, Vahedi H, Mikaeli J, Khatibian M, Massarrat S. Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. Helicobacter 2010; 15: 497-504 [PMID: 21073605 DOI: 10.1111/j.1523-5378.2010.00798.x]
24. Sarkeshikian SS, Iranikhah A, Ghadir MR. Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. Turk J Gastroenterol 2013; 24: 10-14 [PMID: 23794338]
25. Keshavarz AA, Bashiri H, Rahbar M. Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for H pylori eradication in Iranian population. World J Gastroenterol 2007; 13: 930-933 [PMID: 17352026]
26. Seyedmajidi S, Mirsattari D, Zojaji H, Zanganeh E, Seyyedmajidi M, Almasi S, Zali M. Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population. Arab J Gastroenterol 2013; 14: 1-5 [PMID: 23622801 DOI: 10.1016/j.ajg.2012.12.004]
27. Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, doubleblind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients. Dig Dis Sci 2009; 54: 599-603 [PMID: 18594971 DOI: 10.1007/s10620-008-0374-z]
28. Aladaʇ M, Kantarçeken B, Karincaoʇlu M, Sertkaya A, Cikim K, Harputluoʇlu MM, Demirel U, Alan H, Ateş F, Yildirim B, Hilmioʇlu F. Comparison of pantoprazole-vs. omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection and duodenal ulcer healing in a Turkish population. Turk J Gastroenterol 2005; 16: 242-243 [PMID: 16547858]
29. Aydin A, Onder G, Akarca U, Tekin F, Tuncyurek M, Ilter T. Comparison of 1-and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases. Eur J Intern Med 2007; 18: 496-500 [PMID: 17822662 DOI: 10.1016/j.ejim.2007.02.018]
30. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668-671 [PMID: 14991935]
31. Sezikli M, Cetinkaya ZA, Güzelbulut F, Yeşil A, Alt Nöz ME, Ulu N, Ovünç Kurdaş AO. Efficacy of the Combination of Tetracycline, Amoxicillin, and Lansoprazole in the Eradication of Helicobacter pylori in Treatment-Naïve Patients and in Patients Who Are Not Responsive to Clarithromycin-Based Regimens: A Pilot Study. Gut Liver 2012; 6: 41-44 [PMID: 22375169 DOI: 10.5009/gnl.2012.6.1.41]
32. Uygun A, Kadayifçi A, Yeşilova Z, Savaş MC, Ateş Y, Karslioʇlu Y, Ciʇerim M, Baʇci S, Daʇalp K. Recent success of pantoprazole -or lansoprazole-based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. Turk J Gastroenterol 2004; 15: 219-224 [PMID: 16249974]
33. Yaşar B, Abut E, Kayadibi H, Toros B, Sezikli M, Akkan Z, Keskin Ö, Övünç Kurdaş O. Efficacy of probiotics in Helicobacter pylori eradication therapy. Turk J Gastroenterol 2010; 21: 212-217 [PMID: 20931422]
34. Alkim H, Iscan M, Oz F. Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey. Libyan J Med 2011; 6: [PMID: 21912572 DOI: 10.3402/ljm.v6i0.8412]
35. Songür Y, Senol A, Balkarli A, Baştürk A, Cerçi S. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009; 338: 50-53 [PMID: 19474657 DOI: 10.1097/MAJ.0b013e31819c7320]
36. Uygun A, Kadayifci A, Safali M, Ilgan S, Bagci S. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 2007; 8: 211-215 [PMID: 17970879 DOI: 10.1111/j.1751-2980.2007.00308.x]
37. Nadir I, Yonem O, Ozin Y, Kilic ZM, Sezgin O. Comparison of two different treatment protocols in Helicobacter pylori eradication. South Med J 2011; 104: 102-105 [PMID: 21206418 DOI: 10.1097/SMJ.0b013e318200c209]
38. Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med 2012; 23: 165-168 [PMID: 22284248 DOI: 10.1016/j.ejim.2011.02.011]
39. Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Ther 2008; 30: 528-534 [PMID: 18405790 DOI: 10.1016/j.clinthera.2008.03.009]
40. Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter 2011; 16: 343-345 [PMID: 21923679 DOI: 10.1111/j.1523-5378.2011.00891.x]
41. Milani M, Ghotaslou R, Akhi MT, Nahaei MR, Hasani A, Somi MH, Rafeey M, Sharifi Y. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother 2012; 18: 848-852 [PMID: 22581031 DOI: 10.1007/s10156-012-0425-4]
42. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol 2005; 11: 6009-6013 [PMID: 16273615]
43. Shokrzadeh L, Jafari F, Dabiri H, Baghaei K, Zojaji H, Alizadeh AH, Aslani MM, Zali MR. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol 2011; 17: 261-264 [PMID: 21727733 DOI: 10.4103/1319-3767.82581]
44. Zendedel A, Moradimoghadam F, Almasi V, Zivarifar H. Antibiotic resistance of Helicobacter pylori in Mashhad, Iran. J Pak Med Assoc 2013; 63: 336-339 [PMID: 23914633]
45. Tüzün Y, Bayan K, Yilmaz S, Dursun M, Ozekinci T. The prevalence of primary and secondary Helicobacter pylori resistance to clarithromycin and probable contributing cofactors: data from southeastern Anatolia. Hepatogastroenterology 2008; 55: 289-293 [PMID: 18507127]
46. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88: 33-45 [PMID: 23880479 DOI: 10.1159/000350719]
47. Agah S, Shazad B, Abbaszadeh B. Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia. Saudi J Gastroenterol 2009; 15: 225-228 [PMID: 19794266 DOI: 10.4103/1319-3767.56091]
48. Khatibian M, Ajvadi Y, Nasseri-Moghaddam S, Ebrahimi-Dariani N, Vahedi H, Zendehdel N, Sotoudehmanesh R, Agah S, Mikaeli J, Pourshams A, Ali-Asgari A, Malekzadeh R, Massarrat S. Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease. Arch Iran Med 2007; 10: 161-167 [PMID: 17367217]
49. Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, Vakili A, Saghari M, Massarrat S. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 299-303 [PMID: 10735922 DOI: 10.1046/j.1365-2036.2000.00709.x]
50. Mousavi S, Toussy J, Yaghmaie S, Zahmatkesh M. Azithromycin in one week quadruple therapy for H pylori eradica-tion in Iran. World J Gastroenterol 2006; 12: 4553-4556 [PMID: 16874871]
51. Shidfar F, Agah S, Ekhlasi G, Salehpour A, Ghourchian S. Lycopene an adjunctive therapy for Helicobacter pylori eradication: a quasi-control trial. J Complement Integr Med 2012; 9: Article 14 [PMID: 22850072 DOI: 10.1515/1553-3840.1588]
52. Sotudehmanesh R, Malekzadeh R, Fazel A, Massarrat S, Ziad-Alizadeh B, Eshraghian MR. A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates. J Gastroenterol Hepatol 2001; 16: 264-268 [PMID: 11339416 DOI: 10.1046/j.1440-1746.2001.02416.x]
53. Akyildiz M, Akay S, Musoglu A, Tuncyurek M, Aydin A. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med 2009; 20: 53-57 [PMID: 19237093 DOI: 10.1016/j.ejim.2008.04.003]
54. Köksal AS, Onder FO, Torun S, Parlak E, Sayilir A, Tayfur O, Yildiz H, Ozbalci GS, Kayaçetin E. Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance. Acta Gastroenterol Belg 2013; 76: 34-37 [PMID: 23650780]
55. Sezgin O, Altintaş E, Uçbilek E, Tataroʇlu C. Bismuth-based therapies for the first step eradication of Helicobacter pylori. Turk J Gastroenterol 2006; 17: 90-93 [PMID: 16830288]
56. Kadayifci A, Uygun A, Polat Z, Kantarcioʇlu M, Kilciler G, Başer O, Ozcan A, Emer O. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori. Turk J Gastroenterol 2012; 23: 8-13 [PMID: 22505373]
57. Uygun A, Kadayifci A, Yesilova Z, Ates Y, Safali M, Ilgan S, Bagci S, Dagalp K. Poor efficacy of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori eradication. Indian J Gastroenterol 2007; 26: 174-177 [PMID: 17986746]
58. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. Pylori isolates to metronidazole and tetracycline-comparison of three 3-year studies. Arch Iran Med 2010; 13: 177-187 [PMID: 20433221]
59. Al-Qurashi AR, El-Morsy F, Al-Quorain AA. Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia. Int J Antimicrob Agents 2001; 17: 233-236 [PMID: 11282271 DOI: 10.1016/S0924-8579(00)00336-8]
60. Eltahawy AT. Prevalence of primary Helicobacter pylori resistance to several antimicrobials in a Saudi Teaching Hospital. Med Princ Pract 2002; 11: 65-68 [PMID: 12123105 DOI: 10.1159/000058009]
61. Larbi EB. The changing sensitivity of Helicobacter pylori to metronidazole. Saudi J Gastroenterol 1999; 5: 124-128 [PMID: 19864737]
62. Marie MAM. Patterns of Helicobacter pylori Resistance to Metronidazole, Clarithormycin and Amoxicillin in Saudi Arabia. J Bacteriol Virol 2008; 38: 173-178 [DOI: 10.4167/jbv.2008.38.4.173]
63. Ozbey G, Bahcecioglu IH, Nuri Acik M. Resistance Rates to Various Antimicrobial Agents of Helicobacter pylori Isolates in Eastern Turkey. Inter J Mol Clin Microbiol 2012; 2: 148-152
64. Yasser AS, Haneen Y. Treatment of helicobacter pylori, comparison of three regimens, a double blind randomized trial. J Gastroenterol Hepatol Research 2013; 2: 699-702
65. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-1759 [PMID: 10406231 DOI: 10.1111/j.1572-0241.1999.01202.x]
66. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73 [PMID: 19755966 DOI: 10.1038/ajg.2009.508]
67. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587 [PMID: 23926315 DOI: 10.1136/bmj.f4587]
68. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129-134 [PMID: 23121338 DOI: 10.1111/hel.12017]
69. Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter 2012; 17: 43-48 [PMID: 22221615 DOI: 10.1111/j.1523-5378.2011.00896.x]
70. Cetinkaya ZA, Sezikli M, Güzelbulut F, Coşgun S, Düzgün S, Kurdaş OO. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin. Helicobacter 2010; 15: 143-147 [PMID: 20402816 DOI: 10.1111/j.1523-5378.2010.00747.x]
71. Yakut M, Çinar K, Seven G, Bahar K, Özden A. Sequential therapy for Helicobacter pylori eradication. Turk J Gastroenterol 2010; 21: 206-211 [PMID: 20931421]
72. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34 [PMID: 22457599 DOI: 10.2147/CEG.S25419]
73. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]
74. Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol 2011; 4: 103-114 [PMID: 21694812 DOI: 10.1177/1756283X103 84171]
75. Erçin CN, Uygun A, Toros AB, Kantarcioʇlu M, Kilciler G, Polat Z, Baʇci S. Comparison of 7-and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turk J Gastroenterol 2010; 21: 12-16 [PMID: 20533106]
76. Seven G, Cinar K, Yakut M, Idilman R, Ozden A. Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin. Turk J Gastroenterol 2011; 22: 582-586 [PMID: 22287402]
77. Sharara AI, Chaar HF, Racoubian E, Moukhachen O, Barada KA, Mourad FH, Araj GF. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 2004; 9: 255-261 [PMID: 15165262 DOI: 10.1111/j.1083-4389.2004.00220.x]
78. Daghaghzadeh H, Emami MH, Karimi S, Raeisi M. Oneweek versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran. J Gastroenterol Hepatol 2007; 22: 1399-1403 [PMID: 17645463 DOI: 10.1111/j.1440-1746.2007.05029.x]
79. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, Massarrat S. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001; 15: 411-416 [PMID: 11207517 DOI: 10.1046/j.1365-2036.2001.00931.x]
80. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19: 89-93 [PMID: 14687170 DOI: 10.1046/j.1365-2036.2003.01822. x]
81. Ghadir MR, Shafaghi A, Iranikhah A, Pakdin A, Joukar F, Mansour-Ghanaei F. Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. Turk J Gastroenterol 2011; 22: 1-5 [PMID: 21480103]
82. Ahmad K, Fatemeh F, Mehri N, Maryam S. Probiotics for the treatment of pediatric helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr 2013; 23: 79-84 [PMID: 23446685]
83. Roghani HS, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol 2003; 18: 778-782 [PMID: 12795748 DOI: 10.1046/j.1440-1746.2003.03058.x]
84. Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M, Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuthcontaining quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. Helicobacter 2013; 18: 280-284 [PMID: 23433200 DOI: 10.1111/hel.12047]
85. Morini S, Zullo A, Hassan C, Lorenzetti R, Stella F, Martini MT. Gastric cardia inflammation: role of Helicobacter pylori infection and symptoms of gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 2337-2340 [PMID: 11513171 DOI: 10.1111/j.1572-0241.2001.04038.x]
86. Kusters JG, Gerrits MM, Van Strijp JA, Vandenbroucke-Grauls CM. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infect Immun 1997; 65: 3672-3679 [PMID: 9284136]
87. van Doorn LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WG, de Boer WA. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46: 321-326 [PMID: 10673291 DOI: 10.1136/gut.46.3.321]
88. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001; 13: 1303-1307 [PMID: 11692055]
89. Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Hige S, Takeda H, Asaka M. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15: 1479-1484 [PMID: 11552922 DOI: 10.1046/j.1365-2036.2001.01063.x]
90. Labenz J, Stolte M, Blum AL, Jorias I, Leverkus F, Sollböhmer M, Bertrams J, Börsch G. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39-43 [PMID: 7672677 DOI: 10.1136/gut.37.1.39]
91. Minakari M, Davarpanah Jazi AH, Shavakhi A, Moghareabed N, Fatahi F. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. Helicobacter 2010; 15: 154-159 [PMID: 20402818 DOI: 10.1111/j.1523-5378.2009.00739.x]
92. Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion 2001; 64: 222-225 [PMID: 11842278 DOI: 10.1159/000048865]
93. Fakheri H, Bari Z, Sardarian H. A modified bismuthcontaining quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter 2012; 17: 264-268 [PMID: 22759325 DOI: 10.1111/j.1523-5378.2012.00946.x]
94. Ermis F, Akyuz F, Uyanikoglu A, Kurt R, Pinarbasi B, Nazik H, Kaymakoglu S, Mungan Z. Second-line levofloxacinbased triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. South Med J 2011; 104: 579-583 [PMID: 21886067]
95. Köksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, Saşmaz N, Ozden A, Sahin B. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients. J Gastroenterol Hepatol 2005; 20: 637-642 [PMID: 15836716 DOI: 10.1111/j.1440-1746.2005.03801.x]
96. Altintaş E, Ulu O, Sezgin O, Aydin O, Camdeviren H. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy. Turk J Gastroenterol 2004; 15: 90-93 [PMID: 15334317]
97. Sharara AI, Chaar HF, Aoun E, Abdul-Baki H, Araj GF, Kanj SS. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter 2006; 11: 231-236 [PMID: 16882325 DOI: 10.1111/j.1523-5378.2006.00416.x]
98. Hsu PI, Peng NJ. H. Pylori Eradication Therapy. Gastroenterol Res Pract 2013; 2013: 935635 [PMID: 23476640 DOI: 10.1155/2013/935635]
99. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008; 27: 346-354 [PMID: 17999716 DOI: 10.1111/j.1365-2036.2007.03573.x]
100. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209-221 [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x]
101. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007; 26: 1537-1542 [PMID: 17903237 DOI: 10.1111/j.1365-2036.2007.03531.x]
102. Sancar M, Izzettin FV, Apikoglu-Rabus S, Besisik F, Tozun N, Dulger G. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. Pharm World Sci 2006; 28: 207-214 [PMID: 17066247 DOI: 10.1007/s11096-006-9021-y]
103. Xia HX, Talley NJ, Keane CT, O'Morain CA. Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes. Dig Dis Sci 1997; 42: 1821-1834 [PMID: 9331143 DOI: 10.1023/A:1018827322470]
104. Gunaid AA, Hassan NA, Murray-Lyon IM. Recurrence of Helicobacter pylori infection 1 year after successful treatment: prospective cohort study in the Republic of Yemen. Eur J Gastroenterol Hepatol 2004; 16: 1309-1314 [PMID: 15618837 DOI: 10.1097/00042737-200412000-00012]
105. Gürel S, Beşişk F, Demir K, Mungan Z, Kaymakoʇlu S, Boztaş G, Cakaloʇlu Y, Yeʇinsü O, Okten A. After the eradication of Helicobacter pylori infection, relapse is a serious problem in Turkey. J Clin Gastroenterol 1999; 28: 241-244 [PMID: 10192611 DOI: 10.1097/00004836-199904000-00011]
106. Mansour-Ghanaei F, Taefeh N, Joukar F, Besharati S, Naghipour M, Nassiri R. Recurrence of Helicobacter pylori infection 1 year after successful eradication: a prospective study in Northern Iran. Med Sci Monit 2010; 16: CR144-CR148 [PMID: 20190685]
107. Najafi M, Sobhani M, Khodadad A, Farahmand F, Motamed F. Reinfection Rate after Successful Helicobacter pylori Eradication in Children. Iran J Pediatr 2010; 20: 58-62 [PMID: 23056683]
108. Tirgar Fakheri H, Eshqi F. The Recurrence Rate of Helicobacter Pylori Infection 2 Years After Eradication. J Mazand Univer Med Sci 2007; 17: 72-78
109. Zendehdel N, Nasseri-Moghaddam S, Malekzadeh R, Massarrat S, Sotoudeh M, Siavoshi F. Helicobacter pylori reinfection rate 3 years after successful eradication. J Gastroenterol Hepatol 2005; 20: 401-404 [PMID: 15740483 DOI: 10.1111/j.1440-1746.2005.03561.x]
110. Siavoshi F, Safari F, Doratotaj D, Khatami GR, Fallahi GH, Mirnaseri MM. Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. Arch Iran Med 2006; 9: 308-314 [PMID: 17061600]
111. Baglan PH, Bozdayi G, Ozkan M, Ahmed K, Bozdayi AM, Ozden A. Clarithromycin resistance prevalence and Icea gene status in Helicobacter Pylori clinical isolates in Turkish patients with duodenal ulcer and functional dyspepsia. J Microbiol 2006; 44: 409-416 [PMID: 16953176]
112. Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. Int J Antimicrob Agents 2002; 19: 155-158 [PMID: 11850169 DOI: 10.1016/S0924-8579(01)00482-4]
113. Alfaresi MS, Elkoush AA. Characterization of clarithromycin resistance in isolates of Helicobacter pylori from the UAE. Indian J Gastroenterol 2010; 29: 116-120 [PMID: 20658326 DOI: 10.1007/s12664-010-0034-z]
114. Zefenkey Z, Naser M, Balach O. Primary clarithromycin resistence of helicobacter pylori by fluorescent in situ hybridization in Aleppo-Syria. Inter J Pharm Pharm Sci 2012; 4: 217-221